MYCN amplification and ATRX mutations are incompatible in neuroblastoma

Journal: Nature Communications

Published: 2020-02-14

DOI: 10.1038/s41467-020-14682-6

Affiliations: 17

Authors: 37

Go to article
Institutions Share
Department of Computational Biology, St. Jude, United States of America (USA) 0.23
Department of Developmental Neurobiology, St. Jude, United States of America (USA) 0.14
Department of Pathology, St. Jude, United States of America (USA) 0.14
Department of Oncology, St. Jude, United States of America (USA) 0.08
Basic Sciences Division, FHCRC, United States of America (USA) 0.07
Institute for Genomic Medicine (IGM), Nationwide Children’s Hospital, United States of America (USA) 0.05
Department of Biostatistics, UF, United States of America (USA) 0.05
Center for Hematologic Oncology, DFCI, United States of America (USA) 0.03
Department of Chemical Biology and Therapeutics, St. Jude, United States of America (USA) 0.03
Cytogenetics Shared Resource, St. Jude, United States of America (USA) 0.03
Center for Advanced Genome Engineering (CAGE), St. Jude, United States of America (USA) 0.03
Department of Immunology, St. Jude, United States of America (USA) 0.03
Division of Oncology, CHOP, United States of America (USA) 0.03
Department of Biostatistics, St. Jude, United States of America (USA) 0.03
St. Jude-Washington University Pediatric Cancer Genome Project, United States of America (USA) 0.02
Howard Hughes Medical Institute (HHMI), United States of America (USA) 0.02
Department of Ophthalmology, UTHSC, United States of America (USA) 0.01

Return